Latest News

Biotech Stocks Are Due to Bounce Back. Vertex Pharmaceuticals Stands Out.

Biotech stocks began the year in much the same way they ended it—by getting hammered. Vertex Pharmaceuticals, however, held its own, and that may be reason enough to start nibbling at its shares.

The sector had a terrible 2021. The iShares Biotechnology exchange-traded fund (ticker: IBB), which weights its holdings by market capitalization, rose 1%, its worst year since 2018, while the equal-weighted SPDR S&P Biotech ETF (XBI) fell 25%, its worst year since at least 2007. This year was supposed to be better, but so far it’s…

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News